A year or two ago, the team at Clinical Ink noticed a lot of growth in CNS and pain trials. These trials are demanding from a data capture standpoint: Complicated eligibility criteria, extensive monitoring requirements, comprehensive data collection, and substantial demands on patients all must be overcome.
Knowing this, we facilitated conversations with key opinion leaders from CROs and pharma in eCOA, ePRO, and direct data capture (DDC), or what might be thought of as an EDC model (learn the difference in this blog). We wanted to know their pain points and expectations for service and technology in this space.
We expected these thought leaders would outline useful bells and whistles — and they did cite a few. But even more importantly, they expressed a universal hunger for experience-based guidance. They understood that trial success depends on both teams and technology: It’s not enough to just be given ePRO/eCOA/DDC as a commodity. These customers wanted an experienced consultative partner that could offer not only the most useful tools, but also the best practices for how to use those technologies in the client’s therapeutic area.
These conversations culminated in Clinical Ink’s specialized pain/CNS/neurology offering.